Tesla stock down 23% from highs as 2025 revenue fell 3% to $94.8B. Energy grew 27% while 3.2M vehicles face FSD probe. Is TSLA a buy now?
Browsing: Stocks
Microsoft (MSFT) stock has crashed 32% from its peak, marking its worst performance since 2009. Is the selloff overdone? Analysis inside.
AMD posted $34.6B with strong AI growth earning a Buy rating. Intel’s $52.9B flat revenue receives a Reduce. Full chip sector comparison inside.
US markets fell sharply Thursday as Trump warned Iran to act before it’s too late. Brent crude surged past $107 while Bitcoin and Ethereum declined.
SentinelOne (S) stock trades near 52-week lows following insider sales and analyst target reductions despite beating Q4 earnings expectations.
Nvidia (NVDA) stock could rally if U.S.-Iran deal eases supply chain pressures. Analysts cite strong margins and AI demand as key upside catalysts.
Warren Buffett’s recession investing strategy revealed: how buying during market downturns helped Berkshire achieve 19.9% annual returns since 1965.
Arm Holdings (ARM) receives analyst upgrades after unveiling AGI CPU chip with Meta partnership. Revenue climbs 26% YoY as Wall Street raises targets.
CrowdStrike (CRWD) vs Palo Alto Networks (PANW): Full comparison of revenue growth, ARR, profitability, and analyst targets. Find the right fit.
Oklo (OKLO) drops 50% in six months as UBS cuts price target to $60. With no revenue until 2028, is the $9.4B valuation justified?
Coinbase (COIN) teams with Better and Fannie Mae to launch crypto-backed mortgages, letting buyers use bitcoin or USDC as down payment collateral.
MARA Holdings (MARA) stock jumped 10% after selling 15,133 bitcoin for $1.1B to eliminate ~$1B in convertible notes, reducing total debt by 30%.
CrowdStrike (CRWD) strengthens Intel and IBM partnerships at RSA 2026, enhancing AI security for endpoints and autonomous SOC operations. Analysts bullish.
Intuitive Machines and Rocket Lab stocks rallied as NASA revealed a $20B moon base plan, shifting focus from Gateway station to permanent lunar infrastructure.
Kodiak Sciences (KOD) stock rises after Zenkuda meets primary endpoint in GLOW2 trial, with 62.5% of patients showing improvement vs. 3.3% on sham.